ArticlePLOS digital health2026
Multi-task deep learning integrating pretreatment MRI and whole slide images predicts induction chemotherapy response and survival in locally advanced nasopharyngeal carcinoma.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting response to induction chemotherapy (IC) and overall survival (OS) is critical for optimizing treatment in patients with locally advanced nasopharyngeal carcinoma (LANPC). This study aimed to develop and validate a multi-task deep learning model integrating pretreatment MRI and whole slide images (WSIs) to predict IC response and OS in LANPC. Pretreatment MRI and WSIs from 404 patients with LANPC were retrospectively collected to construct a multi-task model (MoEMIL) for the simultaneous prediction of early IC response and OS. In our cohort, no progressive disease cases were observed; therefore, the poor responder group consisted exclusively of patients with stable disease. MoEMIL employed multi-instance learning to process WSIs, PyRadiomics and a convolutional neural network (ResNet50) to extract MRI features, and fused multimodal features through a multi-gate mixture-of-experts architecture. Clustering-constrained attention multiple instance learning and gradient-weighted class activation mapping were applied for visualization and interpretation. MoEMIL effectively stratified patients into good and poor IC response groups, achieving areas under the curve of 0.917, 0.869, and 0.801 in the train, validation, and test sets, respectively. In the test set, MoEMIL significantly outperformed the deep learning radiomics model and TNM staging for both endpoints. Compared to the Pathomics model, MoEMIL achieved significant improvement for OS (P = 0.0049) and borderline improvement for IC response (P = 0.064). The model could stratify patients into high- and low-risk OS groups (P < 0.05). MoEMIL might be an adjunctive tool for early induction chemotherapy response prediction and prognostic stratification in LANPC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.